Iroko’s Zorvolex gets second FDA approval

Iroko Pharmaceuticals, a global specialty pharmaceutical company, announced that the Food and Drug Administration has approved Zorvolex (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the management of osteoarthritis pain. Last October, Zorvolex was OK’d for the treatment of mild to moderate acute pain in adults.

Click here to read more.